



Commercial/Healthcare Exchange PA Criteria

Effective: November 2018

Prior Authorization: Short Acting Bronchodilators

Products Affected: Albuterol HFA, Proventil HFA (albuterol); Ventolin HFA (albuterol); Xopenex HFA (levalbuterol); ProAir digihaler (albuterol)

Medication Description: Albuterol is an inhaled, moderately selective short-acting beta-2-receptor agonist (SABA). Albuterol is a racemic mixture of R- and S-isomers, and is widely used as a bronchodilator.

Covered Uses:

1. Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease
2. Prevention of exercise-induced bronchospasm in patients 4 years of age and older

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 12 Months

Other Criteria:

- A. Patient has had a trial and failure of ProAir Respiclick, defined as
 - a. Failure to decrease/control symptoms of bronchospasm; **OR**
- B. Patient has an intolerance or contraindication to ProAir Respiclick, defined as (but not limited to):
 - a. Allergic reaction; **OR**
 - b. Adverse drug reactions

Last Res.3/17/2021

References:

1. Product Information: PROAIR(R) DIGIHALER(TM) oral inhalation powder, albuterol sulfate oral inhalation powder. Teva Respiratory LLC (per manufacturer), Frazer, PA, 2018.
2. Product Information: PROAIR(R) RESPICLICK(R) oral inhalation powder, albuterol sulfate oral inhalation powder. Teva Respiratory (per FDA), Horsham, PA, 2016.
3. Product Information: PROAIR(R) HFA oral inhalation aerosol, albuterol sulfate oral inhalation aerosol. Teva Respiratory, LLC, Horsham, PA, 2010.
4. Product Information: VENTOLIN(R) HFA inhalation aerosol, albuterol sulfate HFA inhalation aerosol. GlaxoSmithKline, Research Triangle Park, NC, 2008.
5. Product Information: PROVENTIL(R) HFA oral inhalation aerosol, albuterol sulfate oral inhalation aerosol. Schering Corporation, Kenilworth, NJ, 2007.
6. Product Information: XOPENEX HFA(R) oral inhalation aerosol, levalbuterol tartrate oral inhalation aerosol. Sunovion Pharmaceuticals Inc (per FDA), Marlborough, MA, 2017.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/2018
2	Update	Added ProAir digihaler	Products Affected	10/28/2019
3	Update	Added Albuterol HFA	Products Affected	1/8/2020
4	Update	Removed ProAir HFA trial from Other Criteria	Other Criteria	10/1/2020



